Measurement of residual disease after neoadjuvant chemotherapy

Journal of Clinical Oncology

Volumn 26, Issue 18, 2008, Pages 3094-

  Abrial, Catherine ^a   Thivat, Emilie ^a   Tacca, Olivier ^a   Durando, Xavier ^a   Mouret Reynier, Marie Ange ^a   Gimbergues, Pierre ^a   Penault Llorca, Frédérique ^a   Chollet, Philippe ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; HISTOPATHOLOGY; LETTER; LYMPH NODE METASTASIS; MEASUREMENT; MEDICAL INFORMATION; MEDICAL LITERATURE; MINIMAL RESIDUAL DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR VOLUME; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; HUMAN; NOTE; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL;

EID: 46449097524     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.7817     Document Type: Letter

References (6)

1. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007
2. Carey LA, Metzger R, Dees EC, et al: American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97:1137-1142, 2005
3. Rajan R, Poniecka A, Smith TL, et al: Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 100:1365-1373, 2004
4. Chollet P, Amat S, Belembaogo E, et al: Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer 89:1185-1191, 2003
5. Amat S, Abrial C, Penault-Llorca F, et al: High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94:255-263, 2005
6. Amat S, Penault-Llorca F, Curé H, et al: Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 20:791-796, 2002